alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 51–75 of 89 studies with an author at Beth Israel Deaconess Medical Center (US) (page 3 of 4) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of these 89 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Cardiac index is associated with brain aging: the Framingham Heart Study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Circulation 2010-08-02

Although observational data cannot establish causality, our findings are consistent with the hypothesis that decreasing cardiac function, even at normal cardiac index levels, is associated with accelerated brain aging. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Performance of Claims-based Alzheimer’s Disease and Related Dementias Algorithms in Medicare Advantage and Fee-for-Service Populations

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Journals of Gerontology Series A 2026-09-17

Overall, both algorithms demonstrated comparable performance in MA and FFS populations, with high specificity (>97.9%) and negative predictive value [NPV] (>92.9%). 5 key findings →

Participants: 5,018 Evidence: low

Full summary, score breakdown and related studies → Original source

Cutaneous Phosphorylated Alpha‐Synuclein in Lewy Body Dementia

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Annals of Clinical and Translational Neurology 2025-12-25

After expert panel review, only 50/67 patients met consensus criteria for DLB, 26/151 controls had a reduced MoCA, and 120/151 controls had a normal MoCA. 5 key findings →

Design: cross-sectional Participants: 151 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Glymphatic System Impairment in Alzheimer's Disease and Idiopathic Normal Pressure Hydrocephalus

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Trends in molecular medicine 2020-01-18

Approximately 10% of dementia patients have idiopathic normal pressure hydrocephalus (iNPH), an expansion of the cerebrospinal fluid (CSF)-filled brain ventricles. iNPH and Alzheimer's disease (AD) both exhibit sleep disturbances, build-up of brain metabolic wastes and amyloid-β (Aβ) plaques, perivascular reactive astrogliosis, and mislocalization of astrocyte aquaporin-4 (AQP4). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Confirmatory factor analysis of the ADNI Neuropsychological Battery

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Brain imaging and behavior 2012-12-01

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a large multi-center study designed to develop optimized methods for acquiring longitudinal neuroimaging, cognitive, and biomarker measures of AD progression in a large cohort of patients with Alzheimer's disease (AD), patients with Mild Cognitive Impairment, and healthy controls. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2005-06-13

Alzheimer disease (AD) is characterized neuropathologically by intracellular neurofibrillary tangles (NFT) and of extracellular senile plaques (SP), the central core of which is amyloid beta-peptide (Abeta) derived from amyloid precursor protein (APP), a transmembrane protein. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries

✓ Peer-reviewed alzhub usefulness score 50 out of 100. JAMA Network Open 2025-05-15

This cross-sectional study examines lecanemeb update among Medicare fee-for-service beneficiaries with Alzheimer disease or mild cognitive impairment and evaluates whether there are disparities among potentially eligible patients. 1 key finding →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The role of higher-level cognitive function in gait: executive dysfunction contributes to fall risk in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Dementia and geriatric cognitive disorders 2007-07-04

Alzheimer's disease (AD) is generally understood as primarily affecting cognition while sparing motor function, at least until the later stages of the disease. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Cell 2012-03-01

cis-trans isomerization of proteins phosphorylated by proline-directed kinases is proposed to control numerous signaling molecules and is implicated in the pathogenesis of Alzheimer's and other diseases. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2003-03-24

L-Arginine is the only endogenous nitrogen-containing substrate of NO synthase (NOS), and it thus governs the production of NO during nervous system development as well as in disease states such as stroke, multiple sclerosis, Parkinson's disease, and HIV dementia. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A cross-national survey of tube-feeding decisions in cognitively impaired older persons

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Journal of the American Geriatrics Society 2000-04-01

Despite the difference in diagnostic indication for tube-feeding, the substitute decision-making process was seriously limited at both sites by poor implementation of the principle of substituted judgement, a need for broader advance directives, and improved transfer of knowledge between clinicians and decision-makers. 1 key finding →

Participants: 46 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Prevalent Cardiovascular Disease and Atrial Fibrillation in Relation to Cerebral Small Vessel Disease Burden

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Brain Sciences 2025-07-29

In 3413 participants (mean age: 59 ± 14 years, 53.4% women), 11% had prevalent CVD or AF, 8% had prevalent CVD, and 4% had prevalent AF. 5 key findings →

Participants: 3,413 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development

✓ Peer-reviewed alzhub usefulness score 48 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2020-11-12

Genome-wide association studies have led to numerous genetic loci associated with Alzheimer's disease (AD). 2 key findings →

Participants: 2,247 Evidence: low

Full summary, score breakdown and related studies → Original source

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2013-07-01

Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Development and evaluation of a decision aid on mammography screening for women 75 years and older

✓ Peer-reviewed alzhub usefulness score 47 out of 100. JAMA internal medicine 2014-03-01

The median age of participants was 79 years, 69% (31 of 45) were of non-Hispanic white race/ethnicity, and 60% (27 of 45) had attended at least some college. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Higher Burden of Cerebral Small Vessel Disease Is Associated With Risk of Incident Stroke in Community‐Dwelling Individuals

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of the American Heart Association 2025-11-06

Among 1154 participants (46% men, mean age 70.9±8.7 years), 92 (8%) developed stroke over a median follow-up of 8.6 years (Q1-Q3: 5.1-12.5). 5 key findings →

Participants: 1,154 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Type 2 diabetes and late-onset Alzheimer’s disease and related dementia: A longitudinal cohort study integrating polygenic risk score

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Journal of Alzheimer s Disease 2025-03-25

T2DM is one of the strong risk factors of ADRD but genetic T2DM effect does not contribute to ADRD risk. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Full text may need a subscription

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed